The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I love an afternoon jump Utah lol.Justifiably looking strong today peeps after that very good Rns -follow the yellow brick road as they say!
At some stage we will get investors from usa, may be an afternoon jump.
Well well well- looks like I was right that we will be getting a operation warp speed style therapeutics push.
So Tim has stated we'll go for the AGILE prog. and also mention the DHSC-led Therapeutics Taskforce- and advising 'If this study continues to be successful' re. Covid research.
We are going stratospheric- a re-rate is in good order and everything will kick off around June so not long to go at all.
Many happy returns chaps- a bad day to be Darientaylor, where your mate Charlie boy
Rising now - 2.2p being paid. I expect short term volatility as we still have a couple months till fruition but the potential by the end of June is immense
2.02 - 2.13 is the real bid/offer at 8:07
Fretfree: a tight spread usually signifies the MMs are well short ... Expect some more yapping from the poodles today.
Sareum usually are about as tight as a Submarine door when it comes to leaking information.
A change for the better . No doubt Boris and Professor J VT will soon be made aware of the possibility of an effective Covid treatment in the pipeline. AND ITS OURS
This RNS quite clearly outlines the potential in the goodies we have available and sends out a very potent message to some of the bigger pharma companies that are out there.
COME AND BUY ME.
A very exciting couple of months here for sure.
Eeeek! Looks like I might be too late to get a cheap top-up! Maybe I already have enough shares to make me rich...time will tell.
It’s pretty obvious the delay was to include a statement after the Government announced the Antivirals task force. Should the task force mention TYK2 then it’s a big headline for us. Especially given the situation in India.
The spread has diminished dramatically this morning - a good sign for the expected opening market? I don't think I've ever seen it so small (2.44%)
Is there anything in the RNS that is likely to drive the price up in the short term and anything in particular that caused the delay in the results? It still seems to err on the side of hope rather than expectation.
Patents not parents
Missed out or shorting, unlucky
To value this company based on revenue is nonsense , you have to value by intangibles, parents etc and then down the line cash flows from commercialisation . However, there is nothing that gets me too excited and I am not sure why people think there is? Am I missing something as to me I see it just as more testing
Yap yap yap yap ... get back on your leash you poodle
hahahaha Darientaylor - hahahahaha.
oh dear. Just cover your short really quickly this morning, i’m sure you will be fine. act quick!
Fantastic...really a company that has had no revenue for another year, thats 12 years with no revenues, just govt grants. let that sink in 12 years....
so financial 'highlights' are a grant received of a whole £174k and a tax credit of £130k, zero revenues and a loss of £550k with market cap of £68 million. what a total joke.... market cap should be around £3 million...about a 95% over valued...
company is so small that the r&d spend equates to 2 people in a shed..this is the epitome of an over valued AIM stock...
Fantastic